nach oben

Investigational New Drugs

Erschienen in:

01.08.2015 | PRECLINICAL STUDIES

Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency

verfasst von: Xinmei Xie, Lin Wang, Wenliang Yang, Ruishuang Yu, Qingli Li, Xiaobin Pang

Erschienen in: Investigational New Drugs | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

We evaluated the utility of chemokine MCP-3 and MDC/CCL22 as molecular adjuvants of DNA vaccines for botulinum neurotoxin serotype A (BoNT/A) in a Balb/c mouse model. Notably, the immunogenicity of the DNA vaccine against BoNT/A was not enhanced using a fusion of the AHc-C antigen with the MCP-3 or MDC/CCL22. Nevertheless, the potency of the DNA vaccine was significantly modulated and enhanced by co-administration of the AHc-C antigen with MCP-3 or MDC/CCL22. This strategy elicited high levels of humoral immune responses and protection against BoNT/A. The enhanced potency was further boosted by co-administration of the AHc-C antigen with both MCP-3 and MDC/CCL22 in Balb/c mice, but not by co-administration of AHc-C antigen with the MCP-3-MDC/CCL22 fusion. Co-immunization with both the MCP-3 and MDC/CCL22 constructs induced the highest levels of humoral immunity and protective potency against BoNT/A. Our results indicated that MCP-3 and MDC/CCL22 are effective molecular adjuvants of the immune responses induced by the AHc-C-expressing DNA vaccine when delivered by co-administration of the individual chemokines, but not when delivered in the form of a chemokine/antigen fusion. Thus, we describe an alternative strategy to the design and optimization of DNA vaccine constructs based on co-administration of the antigen with the chemokine rather than in the form of a chemokine/antigen fusion.

Dhama K, Mahendran M, Gupta PK, Rai A (2008) DNA vaccines and their applications in veterinary practice: current perspectives. Vet Res Commun 32(5):341–356PubMedCrossRef

Ulmer JB, Wahren B, Liu MA (2006) Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 12(5):216–222PubMedCrossRef

Fu J, Zhao B, Dong Z, Sun Y, Luan H, Shen X, Gao X, Gong F, Li S, Song H (2012) Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models. Vaccine 30(12):2187–2196PubMedCrossRef

Rusnak JM, Smith LA (2009) Botulinum neurotoxin vaccines: past history and recent developments. Hum Vaccin 5(12):794–805PubMedCrossRef

Smith LA, Rusnak JM (2007) Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27(4):303–318PubMedCrossRef

Middlebrook JL (2005) Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev 57(9):1415–1423PubMedCrossRef

Villarreal D, Talbott K, Choo D, Shedlock D, Weiner D (2013) Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines 12(5):537–554PubMedCentralPubMedCrossRef

Sallusto F, Lanzavecchia A, Mackay CR (1998) Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 19(12):568–574PubMedCrossRef

Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman D (2011) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10(4):499–511PubMedCentralPubMedCrossRef

10.

Lu S, Wang S, Grimes-Serrano JM (2008) Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 7(2):175–191PubMedCrossRef

11.

Kutzler MA, Weiner DB (2004) Developing DNA vaccines that call to dendritic cells. J Clin Investig 114(9):1241–1244PubMedCentralPubMedCrossRef

12.

Liu M, Wahren B, Karlsson HG (2006) DNA vaccines: recent developments and future possibilities. Hum Gene Ther 17(11):1051–1061PubMedCrossRef

13.

Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82(5):488–496PubMedCrossRef

14.

Negash T, Liman M, Rautenschlein S (2013) Mucosal application of cationic poly(D, L-lactide-co-glycolide) microparticles as carriers of DNA vaccine and adjuvants to protect chickens against infectious bursal disease. Vaccine 31(36):3656–3662PubMedCrossRef

15.

Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW (2002) DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 100(4):1153–1159PubMedCrossRef

16.

Guo J, Fan M, Sun J, Jia R (2009) Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency. Int Immunopharmacol 9(7–8):925–930PubMedCrossRef

17.

Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW (1999) Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17(3):253–258PubMedCrossRef

18.

Sumida SM, McKay PF, Truitt DM, Kishko MG, Arthur JC, Seaman MS, Jackson SS, Gorgone DA, Lifton MA, Letvin NL, Barouch DH (2004) Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 114(9):1334–1342PubMedCentralPubMedCrossRef

19.

Yu Y, Ma Y, Chen Y, Gong Z, Wang S, Yu W, Sun Z (2011) Binding activity and immunogenic characterization of recombinant C-terminal quarter and half of the heavy chain of botulinum neurotoxin serotype A. Hum Vaccins 7(10):1090–1095CrossRef

20.

Ma Y, An H, Wei X, Xu Q, Yu Y, Sun Z (2013) Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant. Hum Vaccin Immunother 9(2):242–249PubMedCentralPubMedCrossRef

21.

Saade F (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11(2):189–209PubMedCentralPubMedCrossRef

22.

Hamzaoui K, Hamzaoui A, Borhani-Haghighi A, Kaabachi W (2014) Increased interleukin 33 in patients with neuro-Behcet’s disease: correlation with MCP-1 and IP-10 chemokines. Cell Mol Immunol 11:613–616PubMedCentralPubMedCrossRef

23.

Mihret A, Bekele Y, Bobosha K, Kidd M (2013) Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect 66(4):357–365PubMedCrossRef

24.

Yu Y, Bai J, Sun Z, Wang S, Zhao M, Chen A, Wang W, Chang Q, Liu S, Qiu W (2013) Effective DNA epitope chimeric vaccines for Alzheimer’s disease using a toxin-derived carrier protein as a molecular adjuvant. Clin Immunol 149(1):11–24PubMedCrossRef

25.

Kim JJ, Yang JS, Dentchev T, Dang K, Weiner DB (2000) Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 20(5):487–498PubMedCrossRef

26.

Frauenschuh A, DeVico AL, Lim SP, Gallo RC, Garzino-Demo A (2004) Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine 23(4):546–554PubMedCrossRef

27.

Song R, Liu S, Leong KW (2007) Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines. Mol Ther 15(5):1007–1015PubMedCentralPubMed

28.

Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW (2002) Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 20(9–10):1466–1474PubMedCrossRef

29.

Li N, Yu YZ, Yu WY, Sun ZW (2011) Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacol Immunotoxicol 33(1):211–219PubMedCrossRef

30.

Zhang X, Divangahi M, Ngai P, Santosuosso M, Millar J, Zganiacz A, Wang J, Bramson J, Xing Z (2007) Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 25(7):1342–1352PubMedCrossRef

Titel: Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency
verfasst von: Xinmei Xie
Lin Wang
Wenliang Yang
Ruishuang Yu
Qingli Li
Xiaobin Pang
Publikationsdatum: 01.08.2015
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 4/2015
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-015-0250-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose

Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie